How government health insurance coverage of novel anti-cancer medicines benefited patients in China – a retrospective analysis of hospital clinical data

BACKGROUND: China started to cover novel medicines for the treatment of major cancers, such as trastuzumab for breast cancer by the government health insurance programs since 2016. Limited data have been published on the use of cancer medications and little is known about how government health insur...

Descripción completa

Detalles Bibliográficos
Autores principales: Diao, Yifan, Lin, Mengbo, Xu, Kai, Huang, Ji, Wu, Xiongwei, Li, Mingshuang, Sun, Jing, Li, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380313/
https://www.ncbi.nlm.nih.gov/pubmed/34419013
http://dx.doi.org/10.1186/s12913-021-06840-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380313/
https://www.ncbi.nlm.nih.gov/pubmed/34419013
http://dx.doi.org/10.1186/s12913-021-06840-3

Ejemplares similares